Provided by Tiger Fintech (Singapore) Pte. Ltd.

Editas Medicine

1.72
-0.0600-3.37%
Pre-market: 1.70-0.0200-1.16%08:31 EDT
Volume:1.91M
Turnover:3.33M
Market Cap:142.72M
PE:-0.60
High:1.83
Open:1.77
Low:1.67
Close:1.78
Loading ...

Editas Medicine Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
24 Feb

Bank of America Securities Sticks to Their Sell Rating for Editas Medicine (EDIT)

TIPRANKS
·
16 Jan

Editas Medicine: Strategic Ambitions and Cautious Optimism in Gene-Editing Advancements

TIPRANKS
·
15 Jan

Editas Medicine Outlines 2025 Strategic Priorities and Milestones

TipRanks
·
14 Jan

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

Zacks
·
14 Jan

Editas Medicine announces strategic priorities, 2025 key milestones

TIPRANKS
·
13 Jan

Editas Medicine Inc - Has Operational Runway Into Q2 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Inc - to Submit at Least One Ind/Cta by 2027

THOMSON REUTERS
·
13 Jan

Editas Medicine Highlights New in Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-Year Strategic Priorities

THOMSON REUTERS
·
13 Jan

Press Release: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities

Dow Jones
·
13 Jan

Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year?

Zacks
·
08 Jan

Editas Medicine to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire
·
06 Jan

Why Is Editas Medicine, Inc. (EDIT) Among the Top CRISPR Stocks to Invest In?

Insider Monkey
·
31 Dec 2024

EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce

Zacks
·
16 Dec 2024

Editas Medicine Cut to Underweight From Neutral by JP Morgan

Dow Jones
·
16 Dec 2024

JPMorgan Downgrades Editas Medicine to Underweight From Neutral

MT Newswires Live
·
16 Dec 2024